Axillary Adenopathy after COVID-19 Vaccine: No Reason to Delay Screening Mammogram

HomeRadiologyVol. 304, No. 3 Previous CommunicationsFree AccessErratumAxillary Adenopathy after COVID-19 Vaccine: No Reason to Delay Screening MammogramStacey Wolfson, Eric Kim, Anastasia Plaunova, Rita Bukhman, Ruth D. Sarmiento, Naziya Samreen, Divya Awal, Monica M. Sheth, Hildegard B. Toth, Linda Moy, Beatriu ReigStacey Wolfson, Eric Kim, Anastasia Plaunova, Rita Bukhman, Ruth D. Sarmiento, Naziya Samreen, Divya Awal, Monica M. Sheth, Hildegard B. Toth, Linda Moy, Beatriu ReigStacey WolfsonEric KimAnastasia PlaunovaRita BukhmanRuth D. SarmientoNaziya SamreenDivya AwalMonica M. ShethHildegard B. TothLinda MoyBeatriu ReigPublished Online:Aug 22 2022https://doi.org/10.1148/radiol.229015MoreSectionsPDF ToolsAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookXLinked In Originally published in:https://doi.org/10.1148/radiol.213227Erratum in:https://doi.org/10.1148/radiol.229015An error appeared in Figure 1: the graph in part A appeared twice; the graph in Figure 1A was changed to appear once. The y-axis has been relabeled to say Number of patients. The Figure 1 legend was revised as follows: (B) Graphs compare patients with LAD and follow-up imaging. Bars show the number of examinations assigned Breast Imaging Reporting and Data System (BI-RADS) category 1 or 2 (negative or benign findings) versus BI-RADS 3 (probably benign finding; short-term follow-up is recommended) recommendations by time after the vaccination.Article HistoryPublished online: Aug 22 2022Published in print: Sept 2022 FiguresReferencesRelatedDetailsCited ByPrevalence of Adenopathy at Chest Computed Tomography After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2GeorgeannMcGuinness, Jeffrey B.Alpert, GeraldineBrusca-Augello, LeaAzour, Jane P.Ko, FarahTamizuddin, Elliott K.Gozansky, William H.Moore2023 | Journal of Computer Assisted Tomography, Vol. 47, No. 1Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting reportHaitamLamtai, SaberBoutayeb, HindMrabti, IbrahimEl Ghissassi, HassanErrihani2022 | Frontiers in Oncology, Vol. 12Recommended Articles Axillary Adenopathy after COVID-19 Vaccine: No Reason to Delay Screening MammogramRadiology2022Volume: 303Issue: 2pp. 297-299BI-RADS Terminology for Mammography Reports: What Residents Need to KnowRadioGraphics2019Volume: 39Issue: 2pp. 319-320Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography DatabaseRadiology2020Volume: 296Issue: 1pp. 32-41BI-RADS Category 3 Is a Safe and Effective Alternative to Biopsy or Surgical ExcisionRadiology2020Volume: 296Issue: 1pp. 42-43Follow-up of COVID-19 Vaccine–related Axillary Lymphadenopathy before 12 Weeks Is UnnecessaryRadiology2022Volume: 305Issue: 1pp. 54-55See More RSNA Education Exhibits Common Questions and Challenging Scenarios of the Daily Practice Using the BI-RADSÂ® AtlasDigital Posters2022Mitigating The Impact Of Coronavirus Disease (COVID-19) Vaccinations On Patients Undergoing Breast Imaging Examinations: A Multimodality Case Based Breast Imaging ReviewDigital Posters2021Axillary Lymphadenopathy In COVID-19 Vaccine Recipients: What To Do?Digital Posters2021 RSNA Case Collection Axillary Adenopathy Secondary to HIVRSNA Case Collection2021 Post vaccination axillary adenopathyRSNA Case Collection2021BI-RADS 4C - High suspicion for malignancyRSNA Case Collection2022 Vol. 304, No. 3 Metrics Altmetric Score Open AccessThis article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.PDF download